Core Insights - Fujian Wancheng Biotechnology Group Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming for a main board listing [1] - The brand "Haoxianglai" under Wancheng Group is the top-ranked brand in China's snack and beverage retail sector, with over 10,000 stores [1] - The adjusted net profit for Wancheng Group is projected to reach RMB 820 million in 2024, a significant turnaround from a loss of RMB 28.1 million in 2023 [1] - In the first half of 2024, the group's revenue reached RMB 22.58 billion, marking a year-on-year increase of 106.9%, with adjusted net profit exceeding the total for the previous year at RMB 920 million [1] - The rapid growth in performance is attributed to the aggressive expansion of the sales network, with store numbers increasing from 4,560 at the end of 2023 to 15,355 in the first half of 2025 [1] Financial Performance - Wancheng Group's revenue for the first half of 2024 was RMB 22.58 billion, reflecting a 106.9% year-on-year growth [1] - The adjusted net profit for the first half of 2024 reached RMB 920 million, surpassing the total profit for the entire previous year [1] - The adjusted net profit forecast for 2024 is RMB 820 million, a recovery from a loss of RMB 28.1 million in 2023 [1] Expansion Strategy - The company plans to use the funds raised from the IPO to support store network and strategic expansion, including exploring overseas market opportunities [2] - Plans include introducing new products and expanding into other categories to diversify the product portfolio [2] - There will be an emphasis on enhancing digital capabilities and strengthening warehousing and logistics infrastructure [2]